Syndax Pharmaceuticals (SNDX) Short term Debt (2020 - 2024)

Syndax Pharmaceuticals' Short term Debt history runs 4 years deep, the most recent figure standing at $12.1 million for Q4 2024.

• In Q4 2024, Short term Debt changed N/A year-over-year to $12.1 million; the TTM figure through Dec 2024 stood at $12.1 million (changed N/A YoY), while the FY2024 annual figure was $12.1 million, changed N/A from the prior year.
• Short term Debt for Q4 2024 stood at $12.1 million, up from $7.2 million in the prior quarter.
• The five-year high for Short term Debt was $12.1 million in Q4 2024, with the low at $2.3 million in Q4 2020.
• The 4-year median for Short term Debt is $7.0 million (2021), against an average of $6.6 million.
• Peak annual rise in Short term Debt reached 2.59% in 2022, while the deepest fall reached 22.97% in 2022.
• Syndax Pharmaceuticals' Short term Debt stood at $2.3 million in 2020, then jumped by 315.27% to $9.5 million in 2021, then decreased by 24.0% to $7.2 million in 2022, then soared by 68.0% to $12.1 million in 2024.
• Business Quant data shows SNDX's Short term Debt at $12.1 million in Q4 2024, $7.2 million in Q2 2022, and $3.6 million in Q1 2022.